LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment
US-based LENZ Therapeutics has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan for the commercialisation of …
Post
-
-
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports …
-
Lilly-Purdue partnership to invest $250m in pharma innovation
Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of up …
-
American Academy of Neurology (AAN) Annual Meeting 2025
The American Academy of Neurology (AAN) Annual Meeting 2025 took place in San Diego, California on April 5-9, 2025. This prestigious …
-
5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
To assess the impact of pharmaceutical policy and market dynamics on market access, GlobalData has conducted a comparative analysis of …
-
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment
US-based LENZ Therapeutics has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan for the commercialisation of …
-
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports …
-
Lilly-Purdue partnership to invest $250m in pharma innovation
Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of up …
-
American Academy of Neurology (AAN) Annual Meeting 2025
The American Academy of Neurology (AAN) Annual Meeting 2025 took place in San Diego, California on April 5-9, 2025. This prestigious …
-
5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
To assess the impact of pharmaceutical policy and market dynamics on market access, GlobalData has conducted a comparative analysis of …
-
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid) …
-
Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales
Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024. The …
-
NewBiologix licenses cell line technology to Recipharm Advanced Bio
Swiss biotechnology company NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio to provide biotech and pharma companies …
-
FDA chief Martin Makary sets June deadline for genAI rollout
The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence (genAI) across the …
-
Haya secures $65m in Series A funds to advance heart failure treatment
Haya Therapeutics has procured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure. The …
